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A B S T R A C T
The application of nanomaterials is regarded nowadays as a highly promising approach for overcoming the
limitations of the currently available cancer treatments, contributing for the creation of more effective, precise,
and safer therapies. In the last years, organosilica nanoparticles arisen as alternatives to the most common
mesoporous silica nanoparticles. The organosilica nanoparticles combine the advantages of the mesoporous
silica, such as structural stability and mesoporous structure, with the increased biocompatibility and biode-
gradability of organic materials. Therefore, the variety of organic bridges that can be incorporated into the silica
matrix allowed the development of new and exciting compositions, properties, and functions for improving the
therapeutic effectiveness of the anticancer nanomedicines.
In this review, the strategies that have been explored to create stimuli-responsive organosilica-based drug
delivery systems are highlighted, describing the practical approaches and mechanisms controlling the drug re-
lease. Additionally, the organosilica nanoparticles surface modifications aimed for increasing the blood circu-
lation time and the tumor targeting are also described.
1. Introduction
In recent years, nanomaterials have been widely employed to de-
velop new biomedical solutions such as biosensors, 3D structures for
tissue engineering, and targeted drug delivery systems [1,2]. Particu-
larly, the development of nanoparticles for cancer therapeutic appli-
cations has been one of the most active fields in nanomedicine. These
approaches take advantage of the nanoparticles innate capacity to ac-
cumulate on the tumor tissue and, therefore, overcome the main lim-
itations associated with cancer conventional therapies (e.g. non-specific
toxicity, low bioavailability, and lack of efficacy) [2,3]. Such feature
prompted the development of a plethora of nanomaterials that can be
composed of organic (e.g. lipids, polymers, and proteins) and inorganic
(e.g. carbon, gold, and silica) materials [4–8].
Among them, the mesoporous silica nanoparticles (MSNs) have at-
tracted the attention of the scientific community due to its simple and
easily scalable synthesis that allows the production of particles with
large surface area, well-defined ordered structure, and tunable pore size
[9]. Specially, the MSNs’ characteristic pore structure allows the en-
capsulation of large amounts of therapeutic agents, protecting them
from premature degradation and avoiding their interaction with
healthy tissues [10–14]. On the other hand, the introduction of pore
gatekeepers (e.g. polymers, nanoparticles or small molecules) creates a
drug delivery system that is capable of controlling, both in space and
time, the drug release in order to increase the antitumoral effect (re-
viewed in detail by [2,15,16]). Nevertheless, there are still crucial
parameters, such as the MSNs’ biodegradation, biosafety, and excretion,
that need to be precisely tuned to allow its broad application in the
nanomedicine field [17,18].
In this way, considering the high biocompatibility and biodegrad-
ability observed in organic drug delivery systems (e.g. liposomes, solid-
lipid nanoparticles, and micelles), researchers started to explore the
introduction of organic moieties into the inorganic silica (Si-O-Si) ma-
trix [19,20]. Further, the almost unlimited options of organosilane
precursors opens the possibility to design and optimize the nano-
particles physicochemical properties and biological performance
[21,22]. Such impelled the creation of a wide number of hybrid silica
structures that can be grouped in two main categories, the periodic
mesoporous organosilicas (PMOs - produced using only organosilica
precursors) and mesoporous organosilica nanoparticles (MONs – com-
bine both conventional silica and organosilica precursors) [23,24]. In
general, the organosilica-based nanoparticles can maintain some
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properties of the original MSNs, such as the hydrothermal and hydro-
lytic stability as well as the ordered porous structure, and combine
them with an improved colloidal stability, biodegradability, bio-
compatibility and stimuli-responsiveness [25,26]. In fact, this organo-
silica structural plasticity allowed the development of various nano-
medicine-based solutions for bioimaging (e.g. magnetic resonance,
fluorescent, and ultrasounds) and therapeutic (e.g. controlled drug
delivery, immunotherapy, and tissue engineering) applications
[20,25,27–29]. In this article, the most recent progresses in organosi-
lica-based nanoparticles for drug delivery in cancer therapy are re-
viewed. Moreover, the different strategies employed for conferring
them a stimuli-responsive drug release profile and a tumor-specific
bioaccumulation will be highlighted. Finally, an overview of the orga-
nosilica-based nanoparticles’ biosafety and biocompatibility is also
provided.
2. Organosilica nanoparticles
The organosilica nanoparticles physico-chemical properties, struc-
tural plasticity, and biocompatibility makes them one of the most
promising hybrid materials for therapeutic applications. In fact, the
organosilica nanomaterials present a controllable size, porous structure,
and pore size [30]. Further, the wide range of organosilica precursors
also allow the researchers to fine-tune the nanoparticle composition,
surface chemistry and dispersibility [22,31]. Additionally, the large
pore volume and tunable pore size allows the encapsulation of in-
creased payloads of therapeutic agents such as chemotherapeutic drugs
or even larger molecules like genetic material and proteins [21,32–35].
Such, combined with a stimuli-sensitive particle degradation, mediated
by the organic constituents present on the particles’ matrix, can be
explored for increasing the treatments specificity and avoid the rapid in
vivo degradation of the therapeutic agents [32,36]. Similarly, the pos-
sibility to control the particle degradation rate also increase the control
over the organosilica nanoparticles half-life in the human body and
clearance rates, improving the biosafety of these drug delivery systems
[37]. On the other hand, the structural plasticity of the organosilica
nanoparticles can also be explored to imprint new functionalities in the
nanomedicines such as fluorescence, photodynamic capacity, or even
tumor targeting [38–43]. Another advantage of organosilica nano-
particles is the commercial availability of several precursors and the
scalability of the synthesis procedure, which allows the large-scale
production and facilitates the translation of these nanomedicines into
the market.
2.1. Synthesis of organosilica nanoparticles
The organosilica nanoparticles (PMOs and MONs) like the MSNs are
usually produced using sol-gel processes (Fig. 1) [24,44]. In general,
during this process occurs the hydrolysis and subsequent condensation
of silane molecules in an aqueous solution under basic or acidic con-
ditions and in the presence of a soft pore template (i.e. surfactants or
amphiphilic polymers) [30]. The base catalysed hydrolysis of the silane
precursors, tetraalkyl silicates (Si(OX4), where X is typically OEt or
OMe) or organosilanes ([(XO)3Si]n-R, where R is an organic group, n ≥
1), creates reactive silanolate species that will condensate and form
stable covalent siloxane bonds with other silane molecules [45]. It is
worth to notice that the organic group can vary from simple organic
bridges (e.g. methylene, ethylene, and propylene) to complex ones (e.g.
aromatic and long hydrocarbon chains composed of N, S or O)
[1,17,20]. The condensation of several tetraalkyl silicates originates
silica structures (SiO2), whereas in the presence of organosilane pre-
cursors originate silsesquioxane ([RSiO3/2]n) matrices [46]. Ad-
ditionally, the soft pore template (e.g. hexadecyltrimethylammonium
bromide (CTAB)) direct the silane precursors condensation to their
surface, usually by exploring the electrostatic interaction between the
positively charged pore template and the negatively charged silanolate
species [2]. In this way, the packing of these coated pore template
structures results in the formation of the nanoparticles [9]. If a mixture
of tetraalkyl silicates and organosilanes is used the particles are usually
denominated as MONs, whereas the solo utilization of organosilanes
originates the PMOs [47–49]. After the organosilica nanoparticles’
synthesis, the soft pore template must be removed to allow the sub-
sequent loading of the therapeutic agents and due to biocompatibility
issues (e.g. the CTAB is highly cytotoxic) [47,49]. In contrast to the
MSNs, the purification of organosilica nanoparticles demands the uti-
lization of less aggressive extraction procedures in order to preserve the
organic content [30]. Therefore, the solvent extraction or dialysis ap-
proaches have been the most explored extraction protocols for both
MONs and PMOs [50–52].
Nevertheless, it is important to refer that the introduction of the
organosilanes on the sol-gel process is still a challenging step. In fact,
the size, electric charge, chemical composition and wettability of the
organosilane precursors are crucial factors that influence the interac-
tion of the silanolate species with the pore template agents. Such in-
teraction is of paramount importance for the characteristic porous
structure of the nanoparticles or even for the synthesis of uniform and
monodisperse organosilica nanoparticles. In this way, the selection of
the organosilane precursor is crucial for the production of nanoparticles
aimed for biomedical applications. For example, Guan and colleagues
observed that the alteration on the organosilane precursor from me-
thylene to ethylene, ethenylene, or phenylene resulted in the formation
of PMOs with different porous structures, 3D hexagonal (P63/mmc),
cubic (Pm3n), 2D hexagonal (P6mm), and wormlike pores, respectively
[53]. Similarly, Croissant et al. described the formation of PMOs with
different morphologies by using 1,4‐bis(triethoxysilyl)ethylene, bis
(3‐ethoxysilylpropyl)disulphide, or its combination [54]. The authors
reported that the single utilization of 1,4‐ bis(triethoxysilyl)ethylene
resulted in the formation of rod-shaped porous PMOs, whereas the bis
(3‐ethoxysilylpropyl)disulphide produced non-porous spherical PMOs.
Moreover, the authors also described the production rod-shaped porous
PMOs with different sizes by combining the two different organosilane
precursors. In the Table 1, it is provided an overview of the different
organosilica precursors used, synthesis approach, and the final prop-
erties of the nanoparticles such as the particle size and charge.
3. Organosilica nanoparticles application in cancer therapy
The organosilica nanoparticles porous structure conjugated with
their structural plasticity can be explored to introduce new function-
alities such as fluorescence, photodynamic capacity, or even tumor
targeting that support the application of these nanomedicines in cancer
therapy [45,63]. Particularly, in tumor drug delivery applications, the
presence of the organic bridges on the silica matrix impacts on their
chemical properties, which can be explored to tune the hydrophobicity/
hydrophilicity or even the surface charge of the pore walls in order to
maximize the drug loading [20,65,66]. In this way, the drug en-
capsulation in the organosilica nanoparticles pores can be achieved
through nanoparticles/drug dispersion methods in order to stimulate
electrostatic or hydrophobic/hydrophilic interactions between the
therapeutic molecules and the nanoparticle pores [47,67].
On the other hand, the same organic bridges can also mediate the
therapeutics release from the organosilica nanoparticles through sti-
muli dependent mechanisms, such as pH, redox potential, and tem-
perature, that trigger the nanoparticle disassembly/destruction (Fig. 2)
[20,67]. Additionally, the organosilica nanoparticles’ surface can be
modified with stimuli-responsive moieties that will work as pore
blocking agents and mediate the drug release in the presence of a
specific stimulus [68]. This superior control over the drug release is
paramount to reduce the interaction with healthy tissues and enhance
the therapeutic outcome [69,70].
In this section, the different approaches explored in the literature to
develop stimuli-responsive organosilica drug delivery systems is
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summarized (please see Table 2). The different organosilica precursors
that can be used and the underlying principles that regulate the ther-
apeutics release are described [66].
3.1. pH-responsive organosilica nanoparticles
The development of pH-responsive nanocarriers for promoting a
tumor-specific drug release is one of the most explored in cancer na-
nomedicine [71,72]. This approach aims to take advantage of the nat-
ural pH gradient that the nanoparticles will encounter when circulating
in the human body [21]. During the nanoparticles’ circulation in the
bloodstream, they will be exposed to a neutral pH value (∼7.4),
however when reaching the tumor tissue the pH decreases to acidic
values (around to 6.5) [47,73,74]. Such difference is attributed to the
limited availability of oxygen and nutrients that favor the lactate pro-
duction (i.e. Warburg effect) and consequent acidification of the ex-
tracellular tumor media [73,75]. Moreover, after the cancer cells in-
ternalization, the nanoparticles are exposed to even more acidic media
in endosomal (pH 5.5–6.0) and lysosomal (pH 4.5–5.0) compartments
[47,76,77]. Liu and colleagues developed doxorubicin(DOX)-loaded
MONs with benzoic-imine bonds that confer them a pH-responsive
degradability and drug release [78].The organosilica nanoparticles
were produced by promoting the co-condensation of a phenylene Schiff
base bridged organosilane precursor and tetraethyl orthosilicate (TEOS)
through a base-catalyzed modified-Stöber method. Additionally, the
MONs’ pores were also blocked by functionalizing their surface with
PEGylated β-cyclodextrins. The authors observed that the incubation in
PBS at pH 7.4 or culture medium supplemented with FBS (10 %) for 24
h did not induce any significant changes on the nanoparticles size and
surface morphology. On the other side, the incubation in PBS (phos-
phate buffered saline) at pH 5.4 for only 8 h resulted in the reduction of
the nanoparticles’ size from 57.8 to 8 nm, which was attributed to the
hydrolysis of the schiff base organic bridge in acidic media, that lead to
nanoparticle disassembly. Moreover, the authors also noticed that this
pH-sensitivity could modulate the DOX release, 10 %, 71 %, and 100 %
of drug release at pH 7.4, 5.9, and 5.4, respectively. In the in vivo stu-
dies, the authors verified that compared to the commercially available
Doxil the MONs pH sensitivity could decrease the DOX systemic toxicity
(i.e. accumulation in the major organs) and improve the antitumoral
effect, final tumor volume of 102.38 and 190.47 mm3 for MONs and
Doxil, respectively. In turn, Wu et al. explored the production of pH-
responsive hollow phenylene (aromatic)-bridged PMOs for delivering
DOX to cancer cells [35]. The hollow PMOs were produced through a
salt-assisted acid etching methodology using 1,4-bis(triethoxysilyl)
benzene (BTEB) as the organosilica precursor. The authors observed
that the DOX release occurs with stable and sustained profile at phy-
siological pH, reaching the 8% in 24 h. However, the replacement of the
release media for a pH 4 buffer solution prompted the drug release,
reaching the 42.4 % in the following 24 h. This behavior is attributed to
the establishment of drug/nanoparticle phenylene bridges interactions
(e.g. π–π stacking), which decreases with the pH acidification favoring
the drug diffusion. Moreover, the authors observed that DOX delivery
mediated by hollow phenylene (aromatic)-bridged PMOs could improve
the cytotoxicity against DOX resistant MCF-7 (cancer cells, 90 % and 70
% of cell viability for free drug and PMOs treated groups, respectively).
Similarly, Moorthy and coworkers produced pH responsive MONs for
mediating the dual-drug delivery to breast cancer cells [79]. In their
approach, an organosilane precursor was produced by reacting
2,6‐diaminopyridine with triethoxy(3-isocyanatopropyl)silane origi-
nating a bissilylated pyridine bridged diurea derivative. Then, the
MONs were produced by inducing the co-condensation of the synthe-
sized organosilane precursor and TEOS under acidic conditions and
using Pluronic P123 as pore structuring agent. The authors observed
that the MONs drug loading could be achieved through the establish-
ment of hydrogen bounds and electrostatic interactions with the orga-
nosilane bridges in the nanoparticle matrix. Further, the authors no-
ticed that these interactions conferred to the MONs a pH responsive
drug release profile. In fact, the 5-fluorouracil presented a sustained
release in physiological-like medium (10 % of drug released at pH 7.4)
that was accelerated in acidic pH (87 % drug released at pH 5.5). This
sharp difference on the release profile was attributed to the protonation
state of the pyridyle groups on the organosilane bridges, which at pH
7.4 allow the establishment of hydrogen bonds with 5-fluorouracil that
are lost with the pyridyle groups protonation in acidic pH, occurring a
strong electrostatic repulsion that favor the drug release. In the in vitro
cancer cell cultures, the authors observed only a small decrease in the
MCF-7 cells viability (10 % of dead cells) when the MONs where ad-
ministered with culture media at pH 7.4. Nevertheless, the MONs ad-
ministration under acidic media (pH 6.0) decrease the cancer cells
viability in ≈90 %.
Apart from the utilization of organosilane bridge to mediate the
nanoparticles’ pH-responsivity, the controlled drug release profile on
organosilica nanoparticles can also be controlled by pore blocking
moieties grafted on its surface. Parambadath et al. created a pH-re-
sponsive organosilica nanoparticle by blocking the pore openings with
N-[3-(trimethoxysilyl)propyl]aniline/β-cyclodextrin (β-CD) nanovalves
[80]. The MONs were produced by promoting the co-condensation of
N'-bis[3-(triethoxysilyl)propyl] ethyl-enediamine (TESEN) and
Fig. 1. Schematics of the organosilica nanoparticles’ synthesis and matrix structure.
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tetramethyl orthosilicate (TMOS) under basic conditions and using
CTAB as pore structuring agent. Then, the MONs surface was modified
with N-[3-(trimethoxysilyl)propyl]aniline and then, after the drug
loading, functionalized with β-CD through host-guest interactions. The
authors observed that the pH responsive nanovalves could prevent the
drug leakage at pH 7.4, 1 % of the drug released. However, the MONs
incubation in acidic medium (pH 4) resulted in the release of 80 % of 5-
fluorouracil, which is justified by TESEN protonation and consequent
disassembly of the β-CD nanovalves (Fig. 3).
Hu and colleagues also explored the MONs surface functionalization
to develop a pH responsive antitumoral drug delivery system [47]. In
their approach, MONs were produced through the co-condensation of
TEOS and bis[3-(triethoxysilyl)propyl]tetrasulfide (BTES) under basic
conditions and using cetyltrimethylammonium chloride as pore struc-
turing agent. Afterwards, the MONs were functionalized with poly-
acrylic acid and glutathione (GSH) for controlling the drug release and
enhance the cells internalization, respectively. The authors observed
that the amount of DOX released increased with the acidification of the
release medium, 7%, 16.1 %, and 45.5 % at pH 7.4, 6.5, and 5, re-
spectively. This behavior is mediated by the protonation of the GSH
grafted polyacrylic acid chains, decreasing the electrostatic interaction
with the DOX and allowing its diffusion to the outer medium. Fur-
thermore, the authors observed in the in vitro assays that the con-
jugation of the GSH-mediated enhanced cellular uptake with the MONs
pH-responsive drug delivery could reduce the HeLa cancer cells viabi-
lity in 80 % using low nanoparticle concentrations (10 μg/mL).
3.2. Redox-triggered release
The redox potential is also one of the most explored stimuli-triggers
that have been explored to create drug delivery nanosystems with tai-
lored release profiles [81,82]. The drug release from redox responsive
nanoparticles is usually mediated by the degradation of disulfide bonds
(i.e. R-S-S-R) in the presence of reducing agents [83]. For this purpose,
the GSH/glutathione disulfide pair is one of the most important anti-
oxidant defense mechanisms in the human body and its expression in
the cancer cells is 3 orders in magnitude superior to that of the healthy
tissues [84]. Taking this into account, Moghaddam and colleagues de-
veloped redox-responsive MONs for delivering anticancer chemother-
apeutics [37]. The authors produced two different redox-responsive
MONs by promoting the co-condensation of TEOS and bis(triethox-
ysilyl-propyl)-disulfide (BTDS) (disulfide-based MONs) or TEOS and
BTES (tetrasulfide-based MONs) under a basic environment in the
presence of CTAB. The authors reported that the resulting disulfide-
based and tetradisulfide-based MONs presented a similar size (∼110
nm), surface charge (-32 and −27 mV) and pore diameters (2 and 2.7
nm). Nevertheless, the in vitro degradation studies performed in the
GSH presence revealed that the disulfide-based MONs have a higher
degradation rate, reaching the 14 % in 15 days. Further, the authors
also observed that in the absence of GSH the DOX is released in a
sustained fashion from the MONs reaching the 40 % after 15 days,
whereas the addition of GSH can promote a faster DOX release (> 50 %
in 15 days) due to the particles’ degradation. Similarly, Yue et al. de-
veloped MONs containing disulfide bridges to deliver DOX to liver
cancer cells [85]. For that purpose, TEOS and BTES were reacted under
basic conditions in the presence of CTAB. The authors observed that the
resulting MONs were completely degraded after 72 h in PBS containing
10 mM of GSH, in a process mediated by the disruption of the nano-
particle disulfide bonds through reduction reactions. Moreover, the
authors also demonstrated that the DOX release could be accelerated in
Fig. 2. Representation of the approaches explored for developing stimuli-responsive organosilica nanoparticles. The stimuli-responsive drug release can be mediated
by the degradation of the organic bridges present on the nanoparticle matrix or through the utilization of pore capping agents.
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the presence of GSH, < 5 % and 30 % of drug released after 24 h at pH
7.4 in the absence or presence of GSH, respectively. This behavior also
increased the intracellular DOX concentration in HepG2 cancer cells.
Additionally, the superior control over the drug release resulted in an
enhanced antitumoral effect against HepG2 cells when comparing to
conventional mesoporous silica nanoparticles. Huang and colleagues
developed polyethylene glycol functionalized hollow MONS for the
redox responsive DOX release to 4T1 breast cancer tumors [17]. The
hollow PMOs were produced through an etching methodology using
TEOS and BTDS as silica precursors for producing the organosilica
shell. Subsequently, a condensation reaction between the hollow MONs
and Methoxy Polyethylene glycol (PEG) silane was performed to
functionalize the particles’ surface. The authors observed that the
hollow MONs incubation on simulated body fluid containing GSH (10
mM) for 2 days induced a significant degradation on the particles
structure, which were completely degraded in 14 days, whereas in the
absence of GSH the particles remained stable for about 11 days. This
biodegradation capacity was observed in Transmission Electron Mi-
croscopy (TEM) after the nanoparticles’ uptake by 4T1 cancer cells,
with the majority of the nanoparticles collapsing after 2 days and very






























































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 3. Analysis of the 5-fluorouracil (5-Fu) and ibuprofen (IBU) release at
different pH from β-CD capped MONs (a) and (c) and non-capped MONs (b) and
(d). Reprinted from Microporous and Mesoporous Materials, Vol. 215,
Parambadath, S., Mathew, A., Barnabas, M.J., and Ha, C.S., A pH-responsive
drug delivery system based on ethylenediamine bridged periodic mesoporous
organosilica, Pages No.67-75, Copyright (2015), with permission from Elsevier.
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demonstrates the importance of the incorporation of disulfide bridges
on the organic phase of the MONs matrix. Furthermore, the authors
promoted the DOX loading by exploiting hydrophobic interactions be-
tween the drug and particle structure and observed that the hollow
MONs redox-responsive degradation enhanced the drug release. In fact,
the redox responsiveness was clear after 48 h of incubation with 60 %,
30 % and 20 % of drug released with GSH 20 mM, 10 mM, and 0 mM. In
the in vivo assays, the redox-responsive PEGylated hollow MONs were
able to impair the tumor progression more efficiently than free DOX,
tumor-inhibition percentage of 72.2 % and 37.5 % for MONs and free
drug, respectively.
Alternatively, Shen and coworkers produced a pore-capped redox-
responsive MONs for delivering DOX to hepatocarcinoma SMMC-7721
tumors [51]. In this approach, an organosilica layer based on 3-mer-
captopropyl-trimethoxysilane was grown on the surface of mesoporous
silica nucleus and then reacted with maleimide-polyethylene glycol for
blocking the drug release. The authors observed that the MONs in-
cubation in PBS containing GSH (10 mM) induces a layer-based de-
gradation characterized by the initial removal of the PEG superficial
layer followed by the dissociation/degradation of the disulfide-doped
organosilica outer coating. Further, this GSH mediated degradation
could also modulate the DOX release. In fact, the authors registered an
increased DOX release by raising the GSH concentration, 40 % and 72
% of DOX released after 48 h in PBS at pH 7.4 with 2 mM and 10 mM
GSH, respectively. This increased control over the DOX release de-
monstrated to be advantageous on the in vitro cytotoxicity studies. The
authors observed that the MONs (DOX concentration 50 μg/mL) in-
duced the reduction of SMMC-7721 tumor cells viability to 20 %,
whereas in L-02 normal cells only a reduction to 90 % of cell viability
was observed. In the in vivo assays, the PEGylated MONs induced a
tumor inhibition rate of 71.3 % (free DOX tumor inhibition rate 36.2
%), without inducing significant changes on the rat body weight or
damage to major organs.
3.3. Other stimuli-responsive organosilica nanoparticles
Despite the most common pH- or redox- responsive organosilica
nanoparticles, there are others that release the drugs in response to
other stimuli such as temperature, enzymes, and ultrasounds. For ex-
ample, Shao and colleagues developed near-infrared (NIR)-responsive
PEGylated MONs doped with MoS2 nanosheets to be used in the chemo-
photothermal therapy of breast cancer [86]. For that purpose, thioether
bridged MONs were produced by promoting the co-condensation of
TEOS and 1,4-bis(triethoxysilyl) propane tetrasulfide (TESPTS) under
basic conditions in the presence of CTAB. Then, the particles surface
was modified with 3-aminopropyltrimethoxysilane and incubated with
MoS2 nanosheets and maleimide-polyethylene glycol. The obtained
nanoparticles presented the DOX encapsulated in the mesopores and its
diffusion was blocked by the MoS2/PEG coating. The authors observed
that the MoS2/PEG MONs (1 mg/mL) could mediate a temperature
increase up to 50 °C under NIR laser irradiation (808 nm, 1 W/cm2 for 5
min), which could be explored to accelerate the drug release. In fact, in
the absence of the NIR laser, less than 1 % of the DOX is released in 1 h,
whereas under NIR irradiation increased to 16 %. Such was attributed
to the heat generation and consequent vibration of MoS2 sheets at the
surface of the MONs that decrease the drug/nanoparticle interactions
and to the increased movement of the DOX molecules. Further, the
authors also observed an increased amount of DOX in the interior of
Huh-7 cells after NIR laser irradiation. In the in vitro cytotoxicity stu-
dies, the authors observed that the MoS2/PEG MONs combination of the
controlled DOX delivery with the heat generation (photothermal effect)
could reduce the MCF-7 cells viability to 15 %, whereas the stand-alone
chemotherapeutic or photothermal treatments mediated by the MONs
presented a cellular viability of 49 % and 65 %, respectively.
On the other hand, researchers can also utilize enzymes, that are
overexpressed in the tumor tissues, to trigger the drug release from the
organosilica nanoparticles. In this way, Omar et al. produced enzymatic
responsive PMOs for the DOX delivery to cancer cells [87]. The authors
synthesized two different PMOs by promoting the co-condensation of
an diazobenzene-triethoxysilyl amide with 1,4-bis-(triethoxysilyl)ben-
zene (AZO-E PMOs) or 1,2-bis-(trimethoxysilyl)ethane (AZO-B PMOs)
under basic conditions in the presence of CTAB. The authors observed
that the AZO-B PMOs have a faster degradation profile in the presence
of azoreductase, which translated to a faster drug release, ∼100 % and
Fig. 4. Evaluation of the DOX loading and release from polyethylene glycol functionalized hollow MONS. (A) UV–vis spectra of the DOX solution before and after the
encapsulation procedure. (B) Analysis of the DOX release and (C) TEM images of polyethylene glycol functionalized hollow MONS in the presence or absence of GSH.
(D) Schematics of the MONs degradation in response to the GSH. Reprinted from Biomaterials, Vol 125, Huang, P., Chen, Y., Lin, H., Yu, L., Zhang, L., Wang, L. Zhu,
Y., and Shi, J., Molecularly organic/inorganic hybrid hollow mesoporous organosilica nanocapsules with tumor-specific biodegradability and enhanced che-
motherapeutic functionality, Pages No.23-37, Copyright (2017), with permission from Elsevier.
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∼80 % of DOX was released, after 48 h of incubation with enzyme for
AZO-E and AZO-B PMOs, respectively. In contrast, the AZO-E PMOs
present a superior biocompatibility, 95 % and 60 % of cell viability at a
concentration of 100 μg/mL for AZO-E and AZO-B PMOs, respectively.
Moreover, the authors reported a noticeable decrease in chicken egg
OVCAR-8 tumors size after the administration of the enzyme responsive
PMOs.
Another example of the organosilica nanoparticles plasticity is the
capacity to produce drug delivery systems that are responsive to mul-
tiple stimulus, allowing to enhance the spatial-temporal control of the
cargo release. In this field, one of the most common approaches is to
combine the pH and redox sensitivity to modulate the drug release. Rao
and colleagues produced a cystamine (Cys)-integrated MON for the
dual-stimuli responsive delivery of DOX to HeLa cancer cells [67]. For
that purpose, the authors synthesized a Cys containing organosilica
precursor by reacting 3-(Triethoxysilyl)propylsuccinic anhydride with
Cys hydrochloride. Then, the organosilica precursor was co-condensed
with TEOS under basic condition in the presence of CTAB. The in-
corporation of the organic bridge increases the interaction of the DOX
with the nanoparticle matrix improving the drug loading though the
complexation of the carboxylic groups on the Cys-integrated MON and
the amino groups of DOX. Moreover, the authors observed that the DOX
release was increased in the presence of acidic (pH 5.5) and redox (1,4-
dithiothreitol (DTT) 10 mM) conditions due to the pH cleavage and SeS
bonds degradation. In fact, the amount of DOX released increased from
10 % at pH 7.4–56 % and 89 % with the nanoparticles’ incubation at pH
5.5 and pH 5.5/10 mM DTT for 48 h, respectively. In addition, the
authors observed that this behavior influenced the Cys-integrated
MONs cytotoxicity towards HeLa cancer cells. The MONs incubation
with the cancer cells at physiological conditions (pH 7.4) resulted in a
reduction of the cell viability to 83 %, whereas in acidic conditions (pH
5.5) or acidic redox condition (pH 5.5 + 10 mM GSH) the MONs re-
duced the HeLa cells viability to 13 % and 5%, respectively. Similarly,
Ren and coworkers developed a pH- and redox- responsive nanoparticle
based on a ZIF-8 core and a mesoporous organosilica shell for delivering
DOX to HeLa cancer cells [88]. To accomplish that, the organosilica
coating layer was produced through the co-condensation of TEOS and
BTDS under basic conditions in the presence of DOX loaded ZIF-8 cores.
The authors observed that the DOX release could be accelerated by the
acidification of the pH, 20 % and 40 % of DOX released in 48 h at pH
7.4 and 5, respectively. Additionally, the authors also demonstrated
that the addition of DTT 1 mM or 10 mM could further increase the
DOX release to 27 % and 38 % (48 h at pH 7.4), respectively (Fig. 5).
This behavior was attributed to the acid-dependent degradation of the
ZIF-8 cores and to the degradation of the organosilica shell SeS bonds
under reductive environments, as the authors observed in TEM images.
In the in vivo studies, the authors observed that the nanoparticles in-
duced a significant reduction of the tumor weight (inhibition rate of
89.4 %) being observed severe necrotic zones in the histological studies.
Alternatively, Wu et al. developed a thermo- and pH-responsive
MONs coated with MoS2 sheets for deliver DOX to breast cancer [58].
The MONs were produced through the co-condensation of TESPTS and
TEOS under basic conditions in the presence of CTAB. Then, the MONs
surface was modified with 3-mercaptopropyltrimethoxysilane and re-
acted with MoS2 sheets modified with polyethylenimine (PEI), bovine
serum albumin (BSA), and folic acid. The authors observed that the
nanoparticles could mediate an increase in the temperature to 45.8 °C
after NIR (808 nm, 1 W/cm2 for 5 min) laser irradiation. Additionally,
this photothermal capacity could increase the DOX release rate, 2 %
and 15 % after 1 h in the absence or presence of NIR laser irradiation,
due to the heat generation and vibration of the MoS2 nanosheets that
facilitate the drug diffusion. The authors also observed a faster DOX
release with the acidification of the media, 30 % and 60 % drug re-
leased, after 72 h at pH7.4 and 5, in the presence of NIR light irra-
diation. The controlled drug release resulted in an increased biosafety
and longer survival periods in the in vivo assays combined with the
inhibition of the MCF-7 tumors growth with the combinatorial chemo-
photothermal therapy. With a similar approach, Lu and coworkers
Fig. 5. Analysis of the multi-stimuli responsive DOX release from organosilica coated ZIF-8 nanoparticles at (A) pH = 7.4 and (B) 5.0 in the presence of different
concentrations of DTT. TEM images of organosilica coated ZIF-8 nanoparticles after 6, 12, 24, or 48 h or incubation with DTT, scale bar =100 nm. Reprinted with
permission from ACS Appl. Mater. Interfaces, Vol 11, Ren, S.Z., Zhu, D., Zhu, X.H., Wang, B., Yang, Y.S., Sun, W.X., Wang, X.M., Lv, P.C., Wang, Z.C., and Zhu, H.L.,
Nanoscale Metal–Organic-Frameworks Coated by Biodegradable Organosilica for pH and Redox Dual Responsive Drug Release and High-Performance Anticancer
Therapy, Pages No. 20678-20688, Copyright (2019) American Chemical Society.
R.S. Guimarães, et al. Pharmacological Research 155 (2020) 104742
9
created a triple-stimuli responsive copper sulfide doped MONs for the
chemo-photothermal therapy of glioblastoma [36]. For that purpose,
thiol-functionalized yolk-shell MONs were produced through an acid-
etching process based on the co-condensation of TESPTS and TEOS.
Subsequently, the MONs were functionalized with 3-mercaptopropyl-
trimethoxysilane and doped with copper sulfide. The authors demon-
strated that the copper sulfide doping conferred to the MONs photo-
thermal capacity, reaching the 42 °C after the NIR laser irradiation (808
nm, 0.8 W/cm2 for 3 min). Furthermore, due to the disulfide bonds
present on the organosilica matrix, the DOX release could be ac-
celerated by the presence of GSH, 13 % and 40 % of drug released after
8 h in the absence and with GSH. Moreover, the authors also demon-
strated that the presence of NIR light and acidic environment would
also modulate the DOX diffusion, 40 %–62.5 % drug released in the
presence of GSH at pH 7.4 and 5.5 and 10 %–20 % drug released at pH
7.4 without or with NIR laser irradiation. In the in vivo studies, the
authors reported the inhibition of the tumor growth on the group
treated with the copper sulfide doped MONs mediated chemo-photo-
thermal therapy, contrasting with continuous tumor growth observed in
the free drug and single therapy treated groups.
3.4. Surface modifications performed to improve the organosilica-based
nanoparticles accumulation on tumor tissue
The specific delivery of the therapeutic agents to cancer cells is one
of the main objectives in cancer nanomedicine. The nanoparticles ac-
cumulation on the tumor tissue can occur via passive or active targeting
[89–91]. The passive targeting explores the defective vasculature of the
tumor tissue in order to allow the nanoparticles accumulation in this
region [92]. This can occur via the enhanced permeation and retention
(EPR) effect caused by the tumor vessels leaky epithelium and dis-
continuous microvasculature with fenestrations sizes of approximately
400 nm that allows the nanoparticles extravasation to the tumor
[2,93,94]. Recently, it was also described the occurrence of temporary
vascular eruptions that allow the diffusion of the blood vessel content to
the tumor tissue [95]. In this way, the optimization of the nano-
particles’ stability and blood circulation time is essential to increase the
nanoparticles probability to explore this passive accumulation on the
tumor. In fact, various studies already demonstrated that the adsorption
of biomolecules (e.g. proteins) on the nanoparticles’ surface is one of
the most important phenomena impacting the biodistribution, cellular
uptake, and toxicity of the nanomedicines [94,96]. Therefore, the re-
searchers have been exploring the nanoparticles surface passivation
(e.g. PEG, polyoxazolines, and self-materials) to increase the blood
circulation time and consequently the tumor accumulation (Fig. 6)
[2,94,97].
The PEG can improve the nanomaterials hydrophilicity and stability
as well as decrease the surface opsonization and consequent the re-
cognition by the immune system, which can result in an improved ac-
cumulation in the tumor tissue [94]. Zhang and colleagues produced a
DOX loaded MON modified with pH low insertion peptide (pHLIP)-PEG
for the breast cancer therapy [98]. The introduction of the pHLIP-PEG
on the particles surface was achieved by reacting thiol groups on MONs
with the maleimide group on PEG. The authors reported an increase in
the nanoparticles size from 60 nm to 80 nm and a neutralization of the
surface charge from -13.96 mV to -11.19 mV with the inclusion of the
pHLIP-PEG moieties. Additionally, the authors did not observe any
negative effect on the rats weight and major organs after the weekly
administration of pHLIP-PEG MONs for more than 30 days. Similarly,
Huang et al. developed a PEGylated MONs for the chemotherapy of
Fig. 6. Advantages of the organosilica nanoparticles’ functionalization. The surface modification with hydrophilic materials, host cell membranes, and self-peptides
can increase the colloidal stability of the nanomaterials, decrease the protein adsorption and inhibit the recognition by the immune system, which will lead to higher
blood circulation times. Otherwise, the incorporation of targeting agents such as aptamers, polymers, and antibodies confer to the organosilica nanoparticles an
increased specificity towards the target cells or tissue.
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breast cancer [17]. The PEG moieties were introduced on the nano-
particles by promoting the condensation of a methoxy PEG silane in the
MONs surface. In the in vivo studies, no changes were noticed on the
rats weight, serum biochemical levels (e.g. alanine aminotransferase,
blood urea nitrogen and creatinine), and blood components (e.g. mean
corpuscular hemoglobin, white blood count, red blood count, and he-
moglobin), demonstrating the PEGylated MONs biocompatibility.
On the other hand, the nanoparticles specific accumulation on
tumor tissue can be stimulated by using targeting moieties that will
promote ligand-receptor, antigen-antibody, and other forms of mole-
cular recognition with the tumor tissue (e.g. cancer cells, tumor vas-
culature, and stromal constituents) [91]. Lu and coworkers developed
an anti- Her2 affibody targeted PEGylated MON doped with Cy5.5 for
the therapy and imaging of breast cancer [99]. The yolk-shell MONs
were synthesized by promoting the co-condensation of TEOS and
TESPTS, under basic conditions in the presence of CTAB, followed by an
hydrothermal treatment. Then Cy5.5 maleimide and Her2 affibody-
PEG-maleimide were reacted with the MONs and selectively conjugated
in the outer surface through click chemistry of thiol and maleimide
groups. The Her2 is a transmembrane tyrosine kinase receptor that has
been recognized as a major classifier of invasive breast cancer, which
can be used to direct the nanomedicines for these tumors. In fact, the
studies performed in MDA-MB-435 (cell line overexpressing the Her2)
and MCF-7 (cell line without Her2 receptor) cancer cells revealed that
the Her2 affibody targeted MONs have an increased cellular inter-
nalization in MDA-MB-435 cancer cells. On the other hand, the authors
observed an unspecific cellular internalization (i.e. similar uptake both
on MDA-MB-435 and MCF-7 cells) in the groups treated with the
nontargeted formulations. Moreover, they also reported that this im-
proved selectivity resulted in a superior cytotoxicity towards MDA-MB-
435 cells, 60 % and 40 % of cell viability for the groups treated with
DOX loaded MONs and DOX loaded Her2 affibody targeted MONs, re-
spectively. Xu et al. developed hyaluronic acid functionalized PMOs to
perform the targeted chemotherapy of liver cancer [100]. The hya-
luronic acid is the primary binding molecule of CD44, a glycoprotein
overexpressed in various tumors such as breast, liver, and lung cancer.
The PMOs were produced through the co-condensation of
[4‐(4,4,5,5‐tetramethyl‐1,3,2‐dioxaborolan‐2‐yl)‐N‐(3‐(trimethoxysilyl)
propyl)benzamide] and 3‐aminopropyltrimethoxysilane in the presence
of PEI. Then the PMOs surface was modified with hyaluronic acid by
exploring the electrostatic interactions. These authors observed that the
hyaluronic acid targeted PMOs presented a 5-fold increased uptake by
HepG2 cancer cells (overexpressing CD44 receptors) than in normal
NIH 3T3 cells (low CD44 expression), whereas only a 1.7-fold increase
was detected for the nontargeted nanoparticles. Such preferential up-
take resulted in an increased cytotoxicity of hyaluronic acid targeted
PMOs towards HepG2 cancer cells, half maximal inhibitory con-
centration (IC50) of 0.49 μM and 2.1 μM for HepG2 and NIH 3T3 cells,
respectively. Further, they also reported that the IC50 on HepG2 cancer
cells for the nontargeted PMOs was 4 times higher (2 μM) than that of
the targeted PMOs. Similarly, Wu and colleagues produced a folic acid
targeted MON functionalized with MoS2 nanosheets, PEI, and albumin
for the breast cancer chemo-photothermal therapy [58]. These authors
selected folic acid since it is a ligand for the folate receptor: a glyco-
sylphosphatidyinositol-linked protein that captures and transports its
ligands from the extracellular media to the cell cytoplasm; and that is
overexpressed in the majority of cancers (e.g. ovarian, cervical, breast,
and lung). For that purpose, the MONs were synthesized through the
co-condensation of TEOS and TESPTS, followed by the adsorption of
MoS2/PEI/albumin/folic acid complexes. The authors demonstrated
that the MCF-7 cells (folate receptor overexpressing cells) incubated
with the targeted nanoparticles present a stronger DOX fluorescence
than the ones without the targeting moiety. Moreover, they only de-
tected a weak DOX fluorescence in the hepatoma 7402 cells (folate
receptor negative). Moreover, Wu et al. also recorded an increased
cellular apoptosis after the MCF-7 cells incubation with targeted MONs
for 12 h, 13.8 % and 33.9 % apoptotic cells for nontargeted and tar-
geted MONs, respectively (Fig. 7).
4. MONs biocompatibility
The nanoparticles biocompatibility is one of the primordial con-
cerns when biomedical applications are envisioned. Therefore, ex-
tensive in vitro and in vivo toxicological evaluations are essential for
validating the nanomedicines applicability. In fact, one of the main
objectives of the organosilica nanoparticles is to enhance the biode-
gradability and biosafety of silica-based nanomedicines (Fig. 8).
Moghaddam and colleagues developed redox-responsive MONs for
delivering anticancer chemotherapeutics [37]. The authors produced
two different redox-responsive MONs by promoting the co-condensa-
tion of TEOS and BTDS (disulfide-based MONs) or TEOS and BTES
(tetrasulfide-based MONs) under a basic environment in the presence of
CTAB. The authors reported that the resulting disulfide-based and tet-
radisulfide-based MONs presented a similar size (∼110 nm), surface
Fig. 7. Analysis of the folic acid targeted MON functionalized with MoS2 nanosheets induced apoptosis and cellular uptake. (A) Flow cytometry analysis of the MCF-7
cells apoptosis after incubation with folic acid targeted MON functionalized with MoS2 nanosheets (PMOs–DOX@MoS2-PEI–BSA–FA) or non-targeted nanoparticles
(PMOs–DOX@MoS2-PEI) in the presence or absence of laser irradiation. (B) Analysis of the folic acid targeted MON functionalized with MoS2 nanosheets uptake by
MCF-7 or hepatoma 7402 cells. Reprinted from Chemical Engineering Journal, Vol 342, Wu, J., Bremner, D.H., Niu, S., Wu, H., Wu, J., Wang, H., Li, H., and Zhu, L.
M., Functionalized MoS2 nanosheet-capped periodic mesoporous organosilicas as a multifunctional platform for synergistic targeted chemo-photothermal therapy,
Pages No.90-102, Copyright (2017), with permission from Elsevier.
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charge (-32 and −27 mV) and pore diameters (2 and 2.7 nm). Never-
theless, the in vitro degradation studies performed in the GSH presence
revealed that the disulfide-based MONs have a higher degradation rate,
reaching the 14 % in 15 days. Further, the authors also observed that
the disulfide-based nanoparticles presented a superior biocompatibility
with RAW 264.7 macrophages, IC50 of 705 μg/mL and 233 μg/mL for
disulfide-based MONs and tetrasulfide-based MONs, respectively
(Fig. 9).
Similarly, Yue et al. reported the production of MONs with organic
bridges containing disulfide bonds through the co-condensation of
TEOS and bis[3‐(triethoxysily)propyl]tetrasulfide [60]. These authors
observed that the MONs could be completely degraded after 72 h in the
presence of GSH, contrasting to stable mesoporous silica counterparts.
Further, the MONs presented a high biocompatibility (at maximum
concentration of 150 μg/mL) with more than 85 % of the cells (HepG2
or HL-7702) remaining viable, even when the particles were incubated
with the MONs degradation products. Zhang and coworkers also re-
ported the production of hollow MONs composed by organic bridges
containing disulfide bonds for cancer drug delivery [24]. The TEM
images acquired by these researchers revealed that the MONs incuba-
tion in the presence of GSH induce the fast degradation of the nano-
particles in one week. Further, the authors observed that the MONs
administration in healthy Balb/c mice at the doses of 5, 10, and 20 mg/
kg did not induce any negative effects on animal’s weight. Moreover,
the liver and kidneys function indicators (e.g. alanine aminotransferase,
aspartate aminotransferase, blood urea nitrogen, and creatinine), as
well as the blood routine indexes (e.g. white blood count and red blood
count), remained in the normal range. Such data conjugated with the
absence of damages on the histological analysis of the major organs
supports the biosafety of biodegradable MONs.
5. Conclusion and future perspectives
The organosilica nanoparticles conjugate the MSNs’ stability (hy-
drothermal and hydrolytic) and ordered porous structure with the or-
ganic materials improved colloidal stability, biodegradability, bio-
compatibility, and stimuli-responsiveness. In the present review, the
organosilica nanoparticles’ application in cancer nanomedicine, sti-
muli-responsive drug delivery, tumor-specific accumulation, and bio-
compatibility, was highlighted. In fact, the inclusion of organic bridges
on the mesoporous silica matrix offers the possibility to tune the na-
noparticles biodegradation, which can be exploited to control the space
and time of the drug delivery to cancer cells. Moreover, the almost
unlimited organosilica alternatives allow the development of PMOs or
MONs with bioimaging (e.g. magnetic resonance, fluorescent, and ul-
trasounds) and therapeutic (e.g. photothermal, controlled drug de-
livery, and gene therapy) functionalities. Further, as previously sum-
marized, the organosilica nanoparticles also allow the surface
modification with passivation and targeting agents that increase the
blood circulation time and specificity towards the tumor tissue.
Fig. 8. Representation of the biocompatibility issues of pure silica and organosilica nanoparticles. The organosilica nanoparticles can be designed to suffer biological
degradation, which facilitates the removal of the byproducts through common excretion routes or even by metabolism. Otherwise, the non-degradability of pure
silica nanoparticles prompts their accumulation in the cells or tissues. This phenomenon can lead to cytotoxicity and side effects due to formation of radical oxygen
species or even by provoking the cell lysis.
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However, the synthesis scalability and the development of straightfor-
ward production methods are still one of the main challenges in this
field, particularly for PMOs. Further, despite the promising initial re-
ports on the organosilica biosafety, the current results are still too
preliminary and more extensive biodistribution, excretion, hemo‐/his-
tocompatibility, and biodegradation studies must be performed to va-
lidate these nanomedicines.
Nevertheless, the high pre-clinical performance demonstrated by
the organosilica nanoparticles in biomedical applications encourages
further efforts towards the development of more precise and persona-
lized nanomedicines for cancer therapy.
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